Joshua Reed Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Posted by Geri Gentry on Jul 6th, 2026

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) Director Joshua Reed sold 3,053 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the sale, the director directly owned 19,518 shares in the company, valued at $1,048,897.32. This trade represents a 13.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

NASDAQ:SRRK traded up $0.48 on Monday, hitting $55.36. The company had a trading volume of 1,182,357 shares, compared to its average volume of 1,407,918. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $56.54. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67. The firm has a 50 day moving average of $48.43 and a two-hundred day moving average of $46.59.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period last year, the company posted ($0.67) earnings per share. On average, research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Redmile Group LLC boosted its stake in shares of Scholar Rock by 73.7% in the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after purchasing an additional 3,845,775 shares during the last quarter. Orbis Allan Gray Ltd lifted its holdings in Scholar Rock by 1,034.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares during the period. Wellington Management Group LLP lifted its holdings in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after buying an additional 2,521,022 shares during the period. Holocene Advisors LP bought a new stake in Scholar Rock during the third quarter valued at $91,670,000. Finally, Norges Bank bought a new stake in Scholar Rock during the fourth quarter valued at $91,603,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SRRK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Canaccord Genuity Group started coverage on Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price objective for the company. Wedbush raised their target price on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. upped their price target on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 16th. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus price target of $56.00.

Get Our Latest Research Report on SRRK

About Scholar Rock

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).